Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021

The FDA approved subcutaneous nivolumab across all adult solid tumor indications for nivolumab.

Lenvatinib and pembrolizumab plus transarterial chemoembolization improved PFS in intermediate-stage HCC, according to data from LEAP-012 shared at ESMO 2024.

ASCO recently released updated clinical practice guidelines for systemic therapy in patients with advanced hepatocellular carcinoma.

Riccardo Lencioni, MD, discusses EMERALD-1 results, which he says have “opened a new horizon” in liver cancer and point to a paradigm shift soon.

Adjuvant intensity-modulated radiation therapy may prolong RFS in patients with HCC and narrow margins after curative hepatic resection, according to new data.

Tislelizumab’s survival benefit, response rate, durability, and safety compared with sorafenib establishes it as a new first-line option in patients with HCC.

Histotripsy is newly approved noninvasive technology that uses focused ultrasound energy to destroy malignant tissues by inducing mechanical stresses.

Transarterial radioembolization with Y90 plus combination chemotherapy may be effective first-line therapy for patients with unresectable intrahepatic cholangiocarcinoma.

Immune checkpoint inhibitors are safe for patients with advanced liver cancer and cirrhosis, and may be the best treatment option.

Adagrasib has shown promising clinical activity in pretreated advanced solid tumors with a KRAS G12C mutation, including pancreatic and biliary tract cancers.

Atezolizumab plus bevacizumab significantly improved RFS in HCC. Pierce Chow, MBBS, MMed, FRCS(E), FAMS, PhD, discusses how this will affect practice.

Adding pembrolizumab to gemcitabine and cisplatin improved survival in patients with untreated metastatic or unresectable biliary tract cancer. What’s next?